Organovo (NASDAQ:ONVO – Get Free Report) announced its earnings results on Wednesday. The medical research company reported ($0.19) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.21) by $0.02, Zacks reports. Organovo had a negative return on equity of 266.48% and a negative net margin of 10,151.64%. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million.
Organovo Trading Up 0.5 %
ONVO opened at $0.38 on Friday. The firm’s 50 day simple moving average is $0.38 and its two-hundred day simple moving average is $0.45. Organovo has a 1-year low of $0.32 and a 1-year high of $1.74.
Analyst Upgrades and Downgrades
Separately, StockNews.com initiated coverage on Organovo in a research note on Saturday, February 15th. They issued a “sell” rating on the stock.
About Organovo
Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.
Featured Articles
- Five stocks we like better than Organovo
- Investing in Construction Stocks
- As the Magnificent 7 Stalls, These 3 Stocks Are Gaining Momentum
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Gold’s Ascent: Can Miners and ETFs Take Investors to $3,000?
- Financial Services Stocks Investing
- Medtronic’s Expansion Gains Momentum—Time for a Market Shift?
Receive News & Ratings for Organovo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organovo and related companies with MarketBeat.com's FREE daily email newsletter.
